CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)
Cardiovascular Risk and Identification of Potential High-risk Population in Korean Patients With Acute Myocardial Infarction II (COREA-AMI II)
1 other identifier
observational
13,000
1 country
2
Brief Summary
This study is intended to provide contemporary data on the residual cardiovascular risk in all consecutive patients with acute myocardial infarction, especially in patients who survived stably within one-year after percutaneous coronary intervention. In addition, this study will identify which baseline clinical, angiographic, or treatment factors are associated with residual cardiovascular risk and bleeding events
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2004
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2004
CompletedFirst Submitted
Initial submission to the registry
May 31, 2016
CompletedFirst Posted
Study publicly available on registry
June 20, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2018
CompletedJuly 6, 2016
July 1, 2016
13.1 years
May 31, 2016
July 3, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Cumulative incidence of cardiovascular events
Cardiac death, nonfatal myocardial infarction, or nonfatal stroke
5 years
Secondary Outcomes (12)
Cumulative incidence of all-cause death
5 years
Cumulative incidence of cardiac death
5 years
Cumulative incidence of nonfatal myocardial infarction
5 years
Cumulative incidence of nonfatal stroke
5 years
Cumulative incidence of target lesion revascularization
5 years
- +7 more secondary outcomes
Other Outcomes (1)
Cumulative incidence of cardiovascular events beyond first year after percutaneous coronary intervention
From 1 year up to 5 years after percutaneous coronary intervention
Study Arms (2)
High-risk
Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have at least one of the following risk factors: * Age ≥ 65 years * Diabetes mellitus requiring medication * Documented history of a second prior presumed spontaneous MI (\>1 year ago) * Documented history of angiographic evidence of multivessel coronary artery disease * Chronic, non-end stage renal dysfunction
Low-risk
Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have none of the pre-specified risk factors
Interventions
Percutaneous coronary intervention
Eligibility Criteria
Acute myocardial infarction who were treated with percutaneous coronary intervention
You may qualify if:
- Acute myocardial infarction who were treated with percutaneous coronary intervention using stents
You may not qualify if:
- Acute myocardial infarction who were treated with only balloon angioplasty
- Acute myocardial infarction who were managed by conservative strategy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Seoul St. Mary's Hospitallead
- The Catholic University of Koreacollaborator
- Chonnam National Universitycollaborator
- AstraZenecacollaborator
Study Sites (2)
Chonnam National University Hospital
Gwangju, South Korea
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, South Korea
Related Publications (9)
Kim SH, Lee W, Choo EH, Lee KY, Hwang BH, Choi IJ, Lee JM, Yoo KD, Park MW, Park CS, Kim HY, Kim MC, Ahn Y, Chang K. Long-term outcomes of premature acute myocardial infarction: impact of multivessel disease. Coron Artery Dis. 2026 Jan 20. doi: 10.1097/MCA.0000000000001613. Online ahead of print.
PMID: 41555573DERIVEDKim SH, Choo EH, Kang J, Lee JM, Yoo KD, Park MW, Park CS, Kim HY, Kim MC, Ahn Y, Chang K, Kim HS. The efficacy and safety of prasugrel in acute coronary syndrome: a propensity-matched Korean cohort study focused on age and weight of patients. BMC Cardiovasc Disord. 2025 Nov 26;25(1):888. doi: 10.1186/s12872-025-05263-w.
PMID: 41299333DERIVEDKim S, Lee KY, Kim KA, Byeon J, Shin S, Hwang BH, Kim JJ, Choo EH, Kim CJ, Kyoung Sa Y, Park MW, Hyun S, Yoon AH, Ahn Y, Chang K. The role of serum uric acid in survival prediction in patients with acute myocardial infarction accompanied by heart failure with preserved ejection fraction. Front Cardiovasc Med. 2025 Nov 10;12:1622275. doi: 10.3389/fcvm.2025.1622275. eCollection 2025.
PMID: 41293617DERIVEDKim KA, Kim SH, Lee KY, Yoon AH, Hwang BH, Choo EH, Kim JJ, Choi IJ, Kim CJ, Lim S, Park MW, Yoo KD, Jeon DS, Ahn Y, Jeong MH, Chang K. Predictors and Long-Term Clinical Impact of Heart Failure With Improved Ejection Fraction After Acute Myocardial Infarction. J Am Heart Assoc. 2024 Aug 20;13(16):e034920. doi: 10.1161/JAHA.124.034920. Epub 2024 Aug 19.
PMID: 39158557DERIVEDLee M, Lee K, Kim DW, Cho JS, Kim TS, Kwon J, Kim CJ, Park CS, Kim HY, Yoo KD, Jeon DS, Chang K, Kim MC, Jeong MH, Ahn Y, Park MW. Comparative Effectiveness of Long-Term Maintenance Beta-Blocker Therapy After Acute Myocardial Infarction in Stable, Optimally Treated Patients Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2023 Aug;12(15):e028976. doi: 10.1161/JAHA.122.028976. Epub 2023 Jul 26.
PMID: 37493020DERIVEDKim HY, Mok J, Kim JY, Jeon D, Her SH, Park MW, Kim DB, Park CS, Lee JM, Chang K, Jung WS, Ahn Y. Effect of Angiotensin Receptor Blocker Dose in Myocardial Infarction With Preserved Left Ventricular Systolic Function. J Cardiovasc Pharmacol. 2023 Jul 1;82(1):52-60. doi: 10.1097/FJC.0000000000001427.
PMID: 37019077DERIVEDAhn Y, Lee D, Choo EH, Choi IJ, Lim S, Lee KY, Hwang BH, Park MW, Lee JM, Park CS, Kim HY, Yoo KD, Jeon DS, Chung WS, Kim MC, Jeong MH, Ahn Y, Chang K. Association Between Bleeding and New Cancer Detection and the Prognosis in Patients With Myocardial Infarction. J Am Heart Assoc. 2022 Nov 15;11(22):e026588. doi: 10.1161/JAHA.122.026588. Epub 2022 Nov 8.
PMID: 36346059DERIVEDCho KH, Kim MC, Choo EH, Choi IJ, Lee SN, Park MW, Park CS, Kim HY, Kim CJ, Sim DS, Kim JH, Hong YJ, Jeong MH, Chang K, Ahn Y. Impact of Low Baseline Low-Density Lipoprotein Cholesterol on Long-Term Postdischarge Cardiovascular Outcomes in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2022 Sep 6;11(17):e025958. doi: 10.1161/JAHA.122.025958. Epub 2022 Aug 24.
PMID: 36000434DERIVEDLee M, Lee K, Kim DW, Cho JS, Kim TS, Kwon J, Kim CJ, Park CS, Kim HY, Yoo KD, Jeon DS, Chang K, Kim MC, Jeong MH, Ahn Y, Park MW. Relationship of Serial High-Sensitivity C-Reactive Protein Changes to Long-term Clinical Outcomes in Stabilised Patients After Myocardial Infarction. Can J Cardiol. 2022 Jan;38(1):92-101. doi: 10.1016/j.cjca.2021.10.007. Epub 2021 Nov 2.
PMID: 34737035DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kiyuk Chang, MD, PhD
Seoul St. Mary's Hospital
- STUDY DIRECTOR
Youngkeun Ahn, MD, PhD
Chonnam National University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief of the Division of Cardiology
Study Record Dates
First Submitted
May 31, 2016
First Posted
June 20, 2016
Study Start
January 1, 2004
Primary Completion
February 1, 2017
Study Completion
February 1, 2018
Last Updated
July 6, 2016
Record last verified: 2016-07